Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported its fourth-quarter 2025 financial results on Wednesday, with total revenue of $4.71 billion, beating analysts' expectations of $4.37 billion, according to Benzinga Pro.
Revenues increased 11% year-over-year in U.S. dollars or 9% in local currency.
The increase was mainly due to development milestone payments received in connection with the initiation of Phase 3 studies for duvakitug (anti-TL1A) and from higher revenues from key innovative products, partially offset by lower proceeds from the sale of certain product rights and lower revenues from the International Markets segment due to the divestment of a business venture in Japan.
The company on Wednesday said that the fourth quarter of 2025 marks the first quarter in which the key brands collectively delivered approximately $1 billion of revenues.
Austedo (Huntington's disease drug) 2025 sales increased 34% to $2.26 billion, surpassing the management guidance of $2.05 billion – $2.15 billion.
Ajovy (migraine drug) 2025 sales reached $673 million (+30% LC YoY), above the management guidance of $630 million – $640 million.
Uzedy (schizophrenia drug) 2025 revenues were $191 million, up 63%, above the management expectation of $190 million – $200 million.
The generics drug maker reported adjusted earnings of 96 cents, beating the consensus of 68 cents, up from 71 cents reported a year ago.
Richard Francis, Teva's President and CEO, said: "In 2025, our Pivot to Growth strategy drove Teva's third year of consecutive growth, solidifying our transformation into a leading biopharmaceutical company. Our key innovative brands led our growth, reaching $1 billion in revenues in the fourth quarter of 2025 for the first time, and becoming a true engine of sustainable growth."
Outlook
Teva Pharmaceutical expects fiscal year 2026 adjusted earnings of $2.57-$2.77 per share compared to the Street estimate of $2.73.
Teva sees sales between $16.4 billion and $16.80 billion compared to the consensus of $16.89 billion, including Austedo sales of $2.4 billion-$2.55 billion, Ajovy revenue between $750 million-$790 million, and Uzedy sales of $250 million-$280 million.
The company expects fiscal 2026 operating income of $4.55 billion-$4.8 billion, with adjusted EBITDA of $5.0 billion-$5.3 billion.
"Looking ahead, 2026 will be a milestone-rich year with multiple late-stage pipeline readouts across immunology and neurology; the anticipated FDA approval of olanzapine LAI, and important data expected for duvakitug, our anti-TL1A, and for our anti-IL-15 programs.
Together, these pipeline assets represent a potential of over $10 billion, reinforcing our confidence…," Francis continued.
TEVA Price Action: Teva Pharmaceutical Indus shares were down 0.81% at $31.11 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo via Shutterstock
